Clinical significance of the transcription factor (SOX11) expression in the bone marrow of acute myeloid leukemia patients.

BACKGROUND

The prognosis for acute myeloid leukemia (AML) remains poor, underscoring the need for a deeper understanding of its underlying molecular mechanisms.

AIM: To assess the significance of SOX11 gene expression in the clinical features, response to treatment, and survival outcomes of adult patients with AML.

METHODS

This retrospective study enrolled 102 adults with AML. SOX11 gene expression in bone marrow samples was measured using real-time PCR. Data were correlated to the patients' clinical features, response to treatment, and survival rates.

RESULTS

Increased SOX11 expression was significantly associated with the presence of the FLT3-ITD mutation (P < 0.001), the FAB-M2 subtype (P = 0.008), and cytogenetic abnormalities (P = 0.011). However, no significant association was found between SOX11 expression and other clinical laboratory parameters, complete remission, disease-free survival, or overall survival.

CONCLUSION

SOX11 expression may serve as a marker to identify specific subsets of AML patients who could benefit from intensive targeted chemotherapy.